Plus Therapeutics, Inc. (PSTV)
PSTV Stock Price Chart
Explore Plus Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze PSTV price movements and trends.
PSTV Company Profile
Discover essential business fundamentals and corporate details for Plus Therapeutics, Inc. (PSTV) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Jul 2001
Employees
28.00
Website
https://www.plustherapeutics.comCEO
Marc H. Hedrick
Description
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.
PSTV Financial Timeline
Browse a chronological timeline of Plus Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.88, while revenue estimate is $1.11m.
Earnings released on 15 May 2026
EPS came in at -$1.05 falling short of the estimated -$0.95 by -10.53%, while revenue for the quarter reached $1.03m , beating expectations by +5.54%.
Stock split effective on 2 Apr 2026
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Mar 2026
EPS came in at -$0.83 falling short of the estimated -$0.80 by -4.20%, while revenue for the quarter reached $1.36m , beating expectations by +10.63%.
Earnings released on 30 Oct 2025
EPS came in at -$0.04 falling short of the estimated -$0.02 by -100.00%, while revenue for the quarter reached $1.40m , missing expectations by -6.54%.
Earnings released on 14 Aug 2025
EPS came in at -$0.01 surpassing the estimated -$0.09 by +88.89%, while revenue for the quarter reached $1.39m , missing expectations by -6.48%.
Earnings released on 30 May 2025
EPS came in at -$0.56 falling short of the estimated -$0.25 by -125.74%, while revenue for the quarter reached $1.06m , missing expectations by -28.61%.
Earnings released on 27 Mar 2025
EPS came in at -$0.67 falling short of the estimated -$0.51 by -31.37%, while revenue for the quarter reached $1.40m , missing expectations by -6.40%.
Earnings released on 14 Nov 2024
EPS came in at -$0.37 surpassing the estimated -$0.56 by +34.22%, while revenue for the quarter reached $1.46m , missing expectations by -0.70%.
Earnings released on 14 Aug 2024
EPS came in at -$0.71 falling short of the estimated -$0.53 by -33.96%, while revenue for the quarter reached $1.28m , missing expectations by -24.76%.
Earnings released on 15 May 2024
EPS came in at -$0.75 surpassing the estimated -$1.09 by +31.19%, while revenue for the quarter reached $1.68m , missing expectations by -1.35%.
Earnings released on 5 Mar 2024
EPS came in at -$0.70 surpassing the estimated -$1.07 by +34.73%, while revenue for the quarter reached $1.27m , missing expectations by -10.61%.
Earnings released on 31 Oct 2023
EPS came in at -$1.00 falling short of the estimated -$0.58 by -72.41%, while revenue for the quarter reached $1.24m , missing expectations by -33.25%.
Earnings released on 14 Aug 2023
EPS came in at -$0.59 surpassing the estimated -$1.91 by +69.11%, while revenue for the quarter reached $1.90m , beating expectations by +80.44%.
Stock split effective on 1 May 2023
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 20 Apr 2023
EPS came in at -$2.10 matching the estimated -$2.10, while revenue for the quarter reached $506.00k , missing expectations by -31.00%.
Earnings released on 23 Feb 2023
EPS came in at -$2.25 matching the estimated -$2.25, while revenue for the quarter reached $200.00k , missing expectations by -86.52%.
Earnings released on 20 Oct 2022
EPS came in at -$2.85 surpassing the estimated -$3.04 by +6.17%, while revenue for the quarter reached $100.00k , missing expectations by -66.67%.
Earnings released on 21 Jul 2022
EPS came in at -$3.60 falling short of the estimated -$2.70 by -33.33%.
Earnings released on 21 Apr 2022
EPS came in at -$2.85 falling short of the estimated -$2.55 by -11.76%.
Earnings released on 24 Feb 2022
EPS came in at -$4.05 falling short of the estimated -$3.45 by -17.39%.
Earnings released on 21 Oct 2021
EPS came in at -$4.20 falling short of the estimated -$3.15 by -33.33%.
Earnings released on 22 Jul 2021
EPS came in at -$3.75 falling short of the estimated -$3.45 by -8.70%.
PSTV Stock Performance
Access detailed PSTV performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
